Literature DB >> 30206353

Reverse pre-symptomatic testing for Huntington disease: double disclosure when 25% at-risk children reveal the genetic status to their parent.

Adeline Bonnard1, Ariane Herson1, Marcela Gargiulo1,2,3, Alexandra Durr4,5.   

Abstract

Predictive testing for Huntington disease (HD) in 25% at-risk individuals is testing with full knowledge, and sometimes assuming, that the parent does not want to know his status. The goal of this study was to understand: (1) the differences in the motivation between 25% and 50% at-risk individuals to be tested and (2) the consequences of "double disclosure", including parental reactions. Test requests from 25% at-risk individuals were rare (155/1611, 10%). We compared their motivation with those of 1456 50% at-risk individuals. The principal motivation to have the test for both groups was "to know" (48% versus 58%, p = 0.049), but the desire to have children was more frequent in the 25% at-risk group (32% versus 17%, p < 0.001). Sixty percent of the 25% at-risk group went through the testing procedure: 15% (n = 14) were variant positive for HD. Testees reported four adverse reactions of their parent (22%): one committed suicide and three became depressed. This result highlights the impact of "double disclosure", a bad result for the person themselves and the transmitting parent. It is the responsibility of the team to anticipate this outcome with the 25% at-risk individuals: children revealing the genetic status to their parent. They should help the testees and their family to find a satisfactory solution to help prevent adverse reactions. This includes ensuring that the candidate is well-infomed abour the testing options and consequences to her/himself but also to her/his parent. The at-risk parent should be offered to discuss the implications of their child's testing.

Entities:  

Mesh:

Year:  2018        PMID: 30206353      PMCID: PMC6303253          DOI: 10.1038/s41431-018-0255-7

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  18 in total

1.  Recommendations for the predictive genetic test in Huntington's disease.

Authors:  R MacLeod; A Tibben; M Frontali; G Evers-Kiebooms; A Jones; A Martinez-Descales; R A Roos
Journal:  Clin Genet       Date:  2012-07-30       Impact factor: 4.438

2.  Critical periods of suicide risk in Huntington's disease.

Authors:  Jane S Paulsen; Karin Ferneyhough Hoth; Carissa Nehl; Laura Stierman
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

3.  To test or not to test: an ethical conflict with presymptomatic testing of individuals at 25% risk for Huntington's disorder.

Authors:  A N Lindblad
Journal:  Clin Genet       Date:  2001-12       Impact factor: 4.438

4.  Suicidal behavior in prodromal Huntington disease.

Authors:  Jess G Fiedorowicz; James A Mills; Adam Ruggle; Douglas Langbehn; Jane S Paulsen
Journal:  Neurodegener Dis       Date:  2011-06-09       Impact factor: 2.977

5.  Huntington disease: who seeks presymptomatic genetic testing, why and what are the outcomes?

Authors:  Tracey M Scuffham; John C MacMillan
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

6.  United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington's disease.

Authors:  C M Benjamin; A Lashwood
Journal:  Clin Genet       Date:  2000-07       Impact factor: 4.438

7.  22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium.

Authors:  Sheharyar S Baig; Mark Strong; Elisabeth Rosser; Nicola V Taverner; Ruth Glew; Zosia Miedzybrodzka; Angus Clarke; David Craufurd; Uk Huntington's Disease Prediction Consortium; Oliver W Quarrell
Journal:  Eur J Hum Genet       Date:  2016-10       Impact factor: 4.246

8.  Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000.

Authors:  S Creighton; E W Almqvist; D MacGregor; B Fernandez; H Hogg; J Beis; J P Welch; C Riddell; R Lokkesmoe; M Khalifa; J MacKenzie; A Sajoo; S Farrell; F Robert; A Shugar; A Summers; W Meschino; D Allingham-Hawkins; T Chiu; A Hunter; J Allanson; H Hare; J Schween; L Collins; S Sanders; C Greenberg; S Cardwell; E Lemire; P MacLeod; M R Hayden
Journal:  Clin Genet       Date:  2003-06       Impact factor: 4.438

9.  Long-term outcome of presymptomatic testing in Huntington disease.

Authors:  Marcela Gargiulo; Séverine Lejeune; Marie-Laure Tanguy; Khadija Lahlou-Laforêt; Anne Faudet; David Cohen; Josué Feingold; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

10.  Fifteen years of experience in predictive testing for Huntington disease at a single testing center in Victoria, Australia.

Authors:  M Kaye Trembath; Roslyn J Tassicker; Veronica R Collins; Sue Mansie; Leslie J Sheffield; Martin B Delatycki
Journal:  Genet Med       Date:  2006-11       Impact factor: 8.822

View more
  4 in total

1.  Presymptomatic testing of those at 25% risk of autosomal dominant neurodegenerative disease- testing team beware.

Authors:  Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2018-10-05       Impact factor: 4.246

2.  Who and Why? Requests for Presymptomatic Genetic Testing for Amyotrophic Lateral Sclerosis/Frontotemporal Dementia vs Huntington Disease.

Authors:  Maria Del Mar Amador; Marcela Gargiulo; Christilla Boucher; Ariane Herson; Stéphanie Staraci; François Salachas; Fabienne Clot; Cécile Cazeneuve; Isabelle Le Ber; Alexandra Durr
Journal:  Neurol Genet       Date:  2020-12-24

3.  Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus.

Authors:  M Grandis; L Obici; M Luigetti; C Briani; F Benedicenti; G Bisogni; M Canepa; F Cappelli; C Danesino; G M Fabrizi; S Fenu; G Ferrandes; C Gemelli; F Manganelli; A Mazzeo; L Melchiorri; F Perfetto; L G Pradotto; P Rimessi; G Tini; S Tozza; L Trevisan; D Pareyson; P Mandich
Journal:  Orphanet J Rare Dis       Date:  2020-12-14       Impact factor: 4.123

Review 4.  Genetic counseling and testing practices for late-onset neurodegenerative disease: a systematic review.

Authors:  Ashley Crook; Chris Jacobs; Toby Newton-John; Rosie O'Shea; Alison McEwen
Journal:  J Neurol       Date:  2021-03-01       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.